Filgotinib治疗活动性非感染性葡萄膜炎:HUMBOLDT随机临床试验
HUMBOLDT是一项双盲、安慰剂对照、2期随机临床试验,在7个国家26个中心纳入74例活动性非感染性中间型、后型或全葡萄膜炎成人患者,随机接受Filgotinib 200 mg每日一次或安慰剂口服最多52周。第24周治疗失败比例Filgotinib组37.5% vs 安慰剂组67.6%(差值-30.1%,95%CI -56.2%至-4.1%,P=.006),Filgotinib降低了治疗失败风险。试验因商业原因提前终止,未能收集更多安全性或有效性信息。
要点
- 第24周治疗失败:Filgotinib组12/32例(37.5%)vs 安慰剂组23/34例(67.6%),差值-30.1%(95%CI -56.2%至-4.1%,P=.006)。
- 不良事件:Filgotinib组30/37例(81.1%)vs 安慰剂组24/35例(68.6%);严重不良事件5/37例(13.5%)vs 2/35例(5.7%)。
- 试验因商业原因在达到入组目标前提前终止,未能收集该JAK1 preferential抑制剂的更多安全性或有效性信息。
核心结论
- Filgotinib降低了活动性非感染性中间型、后型或全葡萄膜炎患者的治疗失败风险(vs 安慰剂)。
- 试验提前终止阻止了收集该JAK1 preferential抑制剂的更多安全性或有效性信息。
研究设计与样本
- HUMBOLDT为双盲、安慰剂对照、2期随机临床试验,2017年7月至2021年4月在7个国家26个中心开展。
- 纳入年龄≥18岁、经口服泼尼松(每日10-60 mg)至少2周治疗仍活动性非感染性中间型、后型或全葡萄膜炎的患者。
- 参与者按1:1随机接受Filgotinib 200 mg或安慰剂口服每日一次,最多52周。
- 2017年7月26日至2021年4月22日筛查116例,74例随机分配至Filgotinib组(n=38)或安慰剂组(n=36);平均(SD)年龄46(16)岁,女性43/72例(59.7%),2例未接受治疗剂量。
主要发现
- 主要终点第24周治疗失败比例:Filgotinib组12/32例(37.5%)vs 安慰剂组23/34例(67.6%),差值vs安慰剂-30.1%(95%CI -56.2%至-4.1%,P=.006)。
- 不良事件:Filgotinib组30/37例(81.1%)vs 安慰剂组24/35例(68.6%)。
- 严重不良事件:Filgotinib组5/37例(13.5%)vs 安慰剂组2/35例(5.7%)。
- 试验期间无死亡报告。
关键数值与推荐
- 治疗失败为复合终点,由脉络膜视网膜和/或视网膜血管病变、最佳矫正视力、前房细胞和玻璃体混浊分级评估组成。
- 试验因商业原因在达到入组目标前提前终止,商业原因与有效性或安全性无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因商业原因在达到入组目标前提前终止,阻止了收集该JAK1 preferential抑制剂的更多安全性或有效性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options. OBJECTIVE: To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis. DESIGN, SETTING, AND PARTICIPANTS: The HUMBOLDT trial was a double-masked, placebo-controlled, phase 2, randomized clinical trial conducted from July 2017 to April 2021 at 26 centers in 7 countries. Eligible participants (aged ≥18 years) had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite at least 2 weeks of treatment with oral prednisone (10-60 mg per day). INTERVENTIONS: Participants were randomly assigned 1:1 to receive filgotinib, 200 mg, or placebo orally once daily for up to 52 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of participants experiencing treatment failure by week 24. Treatment failure was a composite end point represented by assessment of the presence of chorioretinal and/or retinal vascular lesions, best-corrected visual acuity, and anterior chamber cell and vitreous haze grades. Safety was assessed in participants who received at least 1 dose of study drug or placebo. RESULTS: Between July 26, 2017, and April 22, 2021, 116 participants were screened, and 74 (mean [SD] age, 46 [16] years; 43 female [59.7%] of 72 participants, as 2 participants did not receive treatment doses) were randomly assigned to receive filgotinib (n = 38) or placebo (n = 36). Despite early termination of the trial for business reasons ahead of meeting enrollment targets, a significantly reduced proportion of participants who received filgotinib experienced treatment failure by week 24 vs placebo (12 of 32 participants [37.5%] vs 23 of 34 participants [67.6%]; difference vs placebo -30.1%; 95% CI, -56.2% to -4.1%; P = .006). Business reasons were unrelated to efficacy or safety. Adverse events were reported in 30 of 37 participants (81.1%) who received filgotinib and in 24 of 35 participants (68.6%) who received placebo. Serious adverse events were reported in 5 of 37 participants (13.5%) in the filgotinib group and in 2 of 35 participants (5.7%) in the placebo group. No deaths were reported during the trial. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that filgotinib lowered the risk of treatment failure in participants with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis vs placebo. Although the HUMBOLDT trial provided evidence supporting the efficacy of filgotinib in patients with active noninfectious uveitis, the premature termination of the trial prevented collection of additional safety or efficacy information of this JAK1 preferential inhibitor. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03207815.
引用
- Srivastava SK, Watkins TR, Nguyen QD, et al. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 39023880. doi:10.1001/jamaophthalmol.2024.2439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。